Repare Therapeutics Inc. (RPTX) News
Filter RPTX News Items
RPTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest RPTX News From Around the Web
Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's WhyRepare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications. |
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ InhibitorCAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467. |
Repare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%Key Insights The considerable ownership by private equity firms in Repare Therapeutics indicates that they collectively... |
These Biotech Stocks Could Double Your Money, According To AnalystsThe biotech industry has been in the limelight since the COVID-19 pandemic, with public and private sectors pouring in funds to bolster innovation and the development of relevant drugs. Approximately 63% of public biotech firms reported revenue growth in 2021. Emerging biotech companies, which have annual revenue below $500 million, recorded a median 40% annual revenue growth rate, outpacing industry giants, which reported a lower 35% average annual revenue growth rate. While the pandemic-relate |
Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline ProgressInitial Positive Data from MYTHIC Trial and Preclinical Program Updates |
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsCAMBRIDGE, Mass. & MONTREAL, November 09, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023. |
Repare Therapeutics to Host Investor and Analyst Conference Call and WebcastCAMBRIDGE, Mass. & MONTREAL, November 07, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time. |
Repare Therapeutics to Participate in Two Upcoming Investor ConferencesCAMBRIDGE, Mass. & MONTREAL, November 06, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows: |
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with CamonsertibCAMBRIDGE, Mass. & MONTREAL, October 13, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor. The data are being presented in a plenary session titled, "New Drugs on the Horizon" at the AACR-NCI-EORTC International Conference on Molecular |
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a TurnaroundRepare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |